RATIONALE: Schizotypal personality disorder (SPD) is associated with working memory (WM) impairments that are similar to those observed in schizophrenia. Imaging studies have suggested that schizophrenia is associated with alterations in dopamine D1 receptor availability in the prefrontal cortex (PFC) that may be related to the WM impairments that characterize this disorder. OBJECTIVES: The aim of this study was to characterize prefrontal D1 receptor availability and its relation to WM performance in SPD. METHODS: We used positron emission tomography (PET) and the radiotracer [(11)C]NNC112 with 18 unmedicated SPD and 21 healthy control participants; as an index of D1 receptor availability, binding potential (BP) measures (BPF, BPND, and BPP) were calculated for prefrontal and striatal subregions. To assess WM, SPD participants completed the 2-back and Paced Auditory Serial Addition Test (PASAT). RESULTS: There were no significant group differences in PFC BP. BPF and BPP in the medial PFC were significantly negatively related to PASAT performance (r s = -0.551, p = .022 and r s = -0.488, p = .047, respectively), but BP was not related to 2-back performance. CONCLUSIONS: In contrast to what has been found in schizophrenia, SPD was not associated with significant alterations in prefrontal D1 receptor availability. Similar to previous schizophrenia findings, however, higher prefrontal D1 receptor availability was associated with poorer WM performance (as measured by the PASAT) in SPD. These findings suggest that schizophrenia and SPD may share a common pathophysiological feature related to prefrontal dopamine functioning that contributes to WM dysfunction, but that in SPD, alterations in D1 may occur only in a subset of individuals and/or to an extent that is minor relative to what occurs in schizophrenia.
RATIONALE: Schizotypal personality disorder (SPD) is associated with working memory (WM) impairments that are similar to those observed in schizophrenia. Imaging studies have suggested that schizophrenia is associated with alterations in dopamine D1 receptor availability in the prefrontal cortex (PFC) that may be related to the WM impairments that characterize this disorder. OBJECTIVES: The aim of this study was to characterize prefrontal D1 receptor availability and its relation to WM performance in SPD. METHODS: We used positron emission tomography (PET) and the radiotracer [(11)C]NNC112 with 18 unmedicated SPD and 21 healthy control participants; as an index of D1 receptor availability, binding potential (BP) measures (BPF, BPND, and BPP) were calculated for prefrontal and striatal subregions. To assess WM, SPD participants completed the 2-back and Paced Auditory Serial Addition Test (PASAT). RESULTS: There were no significant group differences in PFC BP. BPF and BPP in the medial PFC were significantly negatively related to PASAT performance (r s = -0.551, p = .022 and r s = -0.488, p = .047, respectively), but BP was not related to 2-back performance. CONCLUSIONS: In contrast to what has been found in schizophrenia, SPD was not associated with significant alterations in prefrontal D1 receptor availability. Similar to previous schizophrenia findings, however, higher prefrontal D1 receptor availability was associated with poorer WM performance (as measured by the PASAT) in SPD. These findings suggest that schizophrenia and SPD may share a common pathophysiological feature related to prefrontal dopamine functioning that contributes to WM dysfunction, but that in SPD, alterations in D1 may occur only in a subset of individuals and/or to an extent that is minor relative to what occurs in schizophrenia.
Authors: Keith H Nuechterlein; Michael F Green; Robert S Kern; Lyle E Baade; Deanna M Barch; Jonathan D Cohen; Susan Essock; Wayne S Fenton; Frederick J Frese; James M Gold; Terry Goldberg; Robert K Heaton; Richard S E Keefe; Helena Kraemer; Raquelle Mesholam-Gately; Larry J Seidman; Ellen Stover; Daniel R Weinberger; Alexander S Young; Steven Zalcman; Stephen R Marder Journal: Am J Psychiatry Date: 2008-01-02 Impact factor: 18.112
Authors: Håkan Fischer; Lars Nyberg; Sari Karlsson; Per Karlsson; Yvonne Brehmer; Anna Rieckmann; Stuart W S MacDonald; Lars Farde; Lars Bäckman Journal: Biol Psychiatry Date: 2010-03-15 Impact factor: 13.382
Authors: A Abi-Dargham; D Martinez; O Mawlawi; N Simpson; D R Hwang; M Slifstein; S Anjilvel; J Pidcock; N N Guo; I Lombardo; J J Mann; R Van Heertum; C Foged; C Halldin; M Laruelle Journal: J Cereb Blood Flow Metab Date: 2000-02 Impact factor: 6.200
Authors: Mark Slifstein; Lawrence S Kegeles; Robyn Gonzales; William G Frankle; Xiaoyan Xu; Marc Laruelle; Anissa Abi-Dargham Journal: J Cereb Blood Flow Metab Date: 2007-02-21 Impact factor: 6.200
Authors: Margaret M McClure; Philip D Harvey; Marianne Goodman; Joseph Triebwasser; Antonia New; Harold W Koenigsberg; Larry J Sprung; Janine D Flory; Larry J Siever Journal: Neuropsychopharmacology Date: 2010-02-03 Impact factor: 7.853
Authors: M Slifstein; B Kolachana; E H Simpson; P Tabares; B Cheng; M Duvall; W Gordon Frankle; D R Weinberger; M Laruelle; A Abi-Dargham Journal: Mol Psychiatry Date: 2008-03-04 Impact factor: 15.992
Authors: Hans Rasmussen; David Erritzoe; Rune Andersen; Bjorn H Ebdrup; Bodil Aggernaes; Bob Oranje; Jan Kalbitzer; Jacob Madsen; Lars H Pinborg; William Baaré; Claus Svarer; Henrik Lublin; Gitte M Knudsen; Birte Glenthoj Journal: Arch Gen Psychiatry Date: 2010-01
Authors: Daniel R Rosell; Lauren C Zaluda; Margaret M McClure; M Mercedes Perez-Rodriguez; K Sloan Strike; Deanna M Barch; Philip D Harvey; Ragy R Girgis; Erin A Hazlett; Richard B Mailman; Anissa Abi-Dargham; Jeffrey A Lieberman; Larry J Siever Journal: Neuropsychopharmacology Date: 2014-07-30 Impact factor: 7.853
Authors: Anissa Abi-Dargham; Jonathan A Javitch; Mark Slifstein; Alan Anticevic; Monica E Calkins; Youngsun T Cho; Clara Fonteneau; Roberto Gil; Ragy Girgis; Raquel E Gur; Ruben C Gur; Jack Grinband; Joshua Kantrowitz; Christian Kohler; John Krystal; John Murray; Mohini Ranganathan; Nicole Santamauro; Jared Van Snellenberg; Zailyn Tamayo; Daniel Wolf; David Gray; Jeffrey Lieberman Journal: Schizophr Bull Date: 2022-01-21 Impact factor: 7.348
Authors: June Sic Kim; Kyung Soon Shin; Wi Hoon Jung; Sung Nyun Kim; Jun Soo Kwon; Chun Kee Chung Journal: BMC Neurosci Date: 2014-09-05 Impact factor: 3.288